Emerging role of precision medicine in biliary tract cancers

Biliary tracts cancers (BTCs) are a diverse group of aggressive malignancies with an overall poor prognosis. Genomic characterization has uncovered many putative clinically actionable aberrations that can also facilitate the prognostication of patients. As such, comprehensive genomic profiling is pl...

Full description

Saved in:
Bibliographic Details
Published in:NPJ precision oncology 2018-10, Vol.2 (1), p.21-21, Article 21
Main Authors: Bogenberger, James M., DeLeon, Thomas T., Arora, Mansi, Ahn, Daniel H., Borad, Mitesh J.
Format: Article
Language:English
Subjects:
692/4017
692/4028
692/53
Cancer
Cancer Research
Cholangiocarcinoma
Gallbladder diseases
Gene Therapy
Human Genetics
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Precision medicine
Review
Review Article
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biliary tracts cancers (BTCs) are a diverse group of aggressive malignancies with an overall poor prognosis. Genomic characterization has uncovered many putative clinically actionable aberrations that can also facilitate the prognostication of patients. As such, comprehensive genomic profiling is playing a growing role in the clinical management of BTCs. Currently however, there is only one precision medicine approved by the US Food and Drug Administration (FDA) for the treatment of BTCs. Herein, we highlight the prevalence and prognostic, diagnostic, and predictive significance of recurrent mutations and other genomic aberrations with current clinical implications or emerging relevance to clinical practice. Some ongoing clinical trials, as well as future areas of exploration for precision oncology in BTCs are highlighted.
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-018-0064-z